A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer

Published:February 13, 2016DOI:



      Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In patients with KRAS-mutant colorectal cancer (CRC), cetuximab alone is ineffective; however, it can bind to tumor cells and induce opsonization for recognition by Imprime PGG-bound innate immune cells. The primary objective of this study was to determine the antitumor activity of Imprime PGG in combination with cetuximab in patients with KRAS-mutant metastatic CRC.

      Patients and Methods

      The study had a 2-stage Simon optimal design with 80% power to detect a target objective response rate (ORR) of ≥10% at a 10% significance level. Patients received weekly Imprime PGG (4 mg/kg) and cetuximab (loading dose, 400 mg/m2, then 250 mg/m2) intravenously. The primary end point was ORR; secondary end points included duration of response (DOR), time to progression (TTP), overall survival (OS), disease control rate, progression-free survival, and safety. Stage 1 of the study was to enroll 17 evaluable patients.


      One partial response (5.6%) was observed among 18 patients enrolled into stage 1. Median DOR was 4.2 months, TTP 2.7 months, and OS 6.6 months. Overall, observed toxicity was as expected from cetuximab alone. The most common (≥20%) adverse events related to Imprime PGG were fatigue (7 patients; 38.9%), infusion reaction (4 patients; 22.2%), and headache (4 patients; 22.2%). There was no Grade 4 toxicity nor treatment-related deaths.


      Imprime PGG in combination with cetuximab treatment in patients with KRAS-mutant CRC showed compelling, albeit modest, clinical activity. This study provides proof of principle that Imprime PGG, in combination with complement-activating antibodies, is associated with clinical activity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.
        • Naishadham D.
        • Jemal A.
        Cancer statistics, 2012.
        CA Cancer J Clin. 2012; 62: 10-29
        • Cutsem E.V.
        • Lang I.
        • Folprecht G.
        • et al.
        Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial.
        ASCO Gastrointestinal Cancers Symposium. 2010; (abstract 281)
        • De Roock W.
        • De Schutter J.
        • De Hertogh G.
        • et al.
        KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab ASCO annual meeting (abstract 4132).
        J Clin Oncol. 2007; 25
        • Bokemeyer C.
        • Kohne C.H.
        • Ciardiello F.
        • et al.
        FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
        Eur J Cancer. 2015; 51: 1243-1252
        • Brown G.D.
        • Gordon S.
        Immune recognition of fungal beta-glucans.
        Cell Microbiol. 2005; 7: 471-479
        • Cain J.A.
        • Newman S.L.
        • Ross G.D.
        Role of complement receptor type three and serum opsonins in the neutrophil response to yeast.
        Complement. 1987; 4: 75-86
        • Vetvicka V.
        • Thornton B.P.
        • Ross G.D.
        Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
        J Clin Invest. 1996; 98: 50-61
        • Xia Y.
        • Vetvicka V.
        • Yan J.
        • Hanikyrova M.
        • Mayadas T.
        • Ross G.D.
        The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
        J Immunol. 1999; 162: 2281-2290
        • Qi C.
        • Cai Y.
        • Gunn L.
        • et al.
        Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans.
        Blood. 2011; 117: 6825-6836
        • Li B.
        • Allendorf D.J.
        • Hansen R.
        • et al.
        Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
        J Immunol. 2006; 177: 1661-1669
        • Li B.
        • Allendorf D.J.
        • Hansen R.
        • et al.
        Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
        Cancer Res. 2007; 67: 7421-7430
      1. Chan AS, Qiu X, Jonas A, Kangas T, Ottoson NR, Bose N. Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T-cell expansion. Presented at the Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, April 18-22, 2015.

      2. Bose N, Chan AS, Jonas A, Qiu X, Ottoson NR. Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells. Presented at the Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, April 18-22, 2015.

        • Hsu Y.F.
        • Ajona D.
        • Corrales L.
        • et al.
        Complement activation mediates cetuximab inhibition of non–small-cell lung cancer tumor growth in vivo.
        Mol Cancer. 2010; 9: 139
        • Milano G.
        • Etienne-Grimaldi M.C.
        • Dahan L.
        • et al.
        Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.
        Ann Oncol. 2008; 19: 2033-2038
        • Chen T.T.
        • Ng T.H.
        Optimal flexible designs in phase II clinical trials.
        Stat Med. 1998; 17: 2301-2312
        • Karapetis C.S.
        • Khambata-Ford S.
        • Jonker D.J.
        • et al.
        K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
        N Engl J Med. 2008; 359: 1757-1765
        • Freeman D.J.
        • Juan T.
        • Reiner M.
        • et al.
        Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
        Clin Colorectal Cancer. 2008; 7: 184-190
        • Amado R.G.
        • Wolf M.
        • Peeters M.
        • et al.
        Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 1626-1634
      3. Price TJ, Peeters M, Kim T, Li J, Cascinu S, Ruff P. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Presented at the European Cancer Congress, Amsterdam, The Netherlands, Sep 27-Oct 01, 2013.

        • Mao C.
        • Huang Y.F.
        • Yang Z.Y.
        • Zheng D.Y.
        • Chen J.Z.
        • Tang J.L.
        KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
        Cancer. 2013; 119: 714-721
        • Nakadate Y.
        • Kodera Y.
        • Kitamura Y.
        • et al.
        KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
        Int J Cancer. 2013; 134: 2146-2155
        • Kohrt H.E.
        • Colevas A.D.
        • Houot R.
        • et al.
        CD137 Activation augments the efficacy of EGFR-targeted therapy.
        J Clin Invest. 2014; 124: 2668-2682